

## AlzeCure Pharma publishes amended Information document regarding rights issue

**At July 4, 2025 an Information document regarding AlzeCure Pharma AB's ("AlzeCure" or the "Company") new share issue with preferential rights for the Company's shareholders of approximately SEK 48.5 million, resolved by the Board of Directors on June 16, 2025 and subsequently approved by an extraordinary general meeting on July 2, 2025, was registered with the Swedish Financial Supervisory Authority and made public. As of today, July 7, 2025, an updated Information Document has been registered with the Swedish Financial Supervisory Authority.**

AlzeCure Pharma has not prepared a prospectus in connection with the new share issue, but has prepared an information document (the "**Information Document**") in accordance with Article 1(4)(i) db) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended, (the "**Prospectus Regulation**"). The Information Document has today been amended with the following text (in English translation):

### Statement regarding postponed disclosure

*The Board of Directors hereby confirms that, at the time of the offer, the Company is not postponing the disclosure of inside information in accordance with Regulation (EU) No 596/2014.*

The amended Information Document, which replaces the previous one, has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation. The Information Document is available on the Company's website, [www.alzecurepharma.com](http://www.alzecurepharma.com) and on Nordic Issuing's website, [www.nordic-issuing.se](http://www.nordic-issuing.se).

### Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise deal in shares, warrants or other securities in AlzeCure. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. Invitation to interested persons to subscribe for shares in AlzeCure will only be made through the amended Information Document that AlzeCure has published on July 7, 2025.

The information in this press release may not be published, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those provided for by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

### For more information, please contact

---

Martin Jönsson, CEO  
Tel: +46 707 86 94 43  
[martin.jonsson@alzecurepharma.com](mailto:martin.jonsson@alzecurepharma.com)

## About AlzeCure Pharma AB (publ)

---

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se).

## Attachments

---

AlzeCure Pharma publishes amended Information document regarding rights issue  
Bilaga IX AlzeCure Pharma AB 7 Juli 2025